Literature DB >> 16461132

Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.

Sun Ying1, Qiu Meng, Glenis Scadding, Abhi Parikh, Chris J Corrigan, Tak H Lee.   

Abstract

BACKGROUND: Impaired braking of inflammatory cell cysteinyl leukotriene production by prostaglandin (PG) E(2) has been implicated in the pathogenesis of aspirin exacerbated airways disease, but the mechanism is obscure. PGE(2) acts via G-protein-coupled receptors, E-prostanoid (EP)(1-4,) but there is little information on the expression of PGE(2) receptors in this condition.
OBJECTIVE: To address the hypothesis that expression of 1 or more EP receptors on nasal mucosal inflammatory cells is deficient in patients with aspirin-sensitive compared with nonaspirin-sensitive polypoid rhinosinusitis.
METHODS: By using specific antibodies, immunohistochemistry, and image analysis, we measured the expression of EP(1-4) in nasal biopsies from patients with aspirin-sensitive (n = 12) and nonaspirin-sensitive (n = 10) polypoid rhinosinusitis and normal controls (n = 9). Double-staining was used to phenotype inflammatory leukocytes expressing EP(1-4).
RESULTS: Global mucosal expression of EP(1) and EP(2), but not EP(3) or EP(4), immunoreactivity was significantly elevated in aspirin-sensitive and nonaspirin-sensitive rhinosinusitis compared with controls (P < .03). This was attributable principally to elevated expression on tubulin(+) epithelial cells and Mucin 5 subtypes A and B (Muc-5AC(+)) goblet cells. In contrast, the percentages of neutrophils, mast cells, eosinophils, and T cells expressing EP(2), but not EP(1), EP(3), or EP(4), were significantly reduced (P < or = .04) in the aspirin-sensitive compared with nonaspirin-sensitive patients.
CONCLUSION: The data suggest a possible role for PGE(2) in mediating epithelial repair in rhinitis and asthma. Because PGE(2) exerts a range of inhibitory actions on inflammatory leukocytes via the EP(2) receptor, its reduced expression in aspirin-sensitive rhinosinusitis may be partly responsible for the increased inflammatory infiltrate and production of cysteinyl leukotrienes that characterize aspirin-sensitive disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461132     DOI: 10.1016/j.jaci.2005.10.037

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  35 in total

Review 1.  Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.

Authors:  Mark Rusznak; R Stokes Peebles
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-02

2.  Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation.

Authors:  Tao Liu; Tanya M Laidlaw; Chunli Feng; Wei Xing; Shiliang Shen; Ginger L Milne; Joshua A Boyce
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

3.  Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Anya J Cutler; Molly S Kidder; Tao Liu; Juan Carlos Cardet; Heng Chhay; Chunli Feng; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2014-01-31       Impact factor: 10.793

4.  Bilateral Inflammatory Aural Polyps: A Manifestation of Samter's Triad.

Authors:  Robert Brobst; Nichole Suss; Stephanie Joe; Saadia Redleaf
Journal:  Int J Otolaryngol       Date:  2010-02-21

5.  Leukotriene D4 and prostaglandin E2 signals synergize and potentiate vascular inflammation in a mast cell-dependent manner through cysteinyl leukotriene receptor 1 and E-prostanoid receptor 3.

Authors:  Vinay Kondeti; Nosayba Al-Azzam; Ernest Duah; Charles K Thodeti; Joshua A Boyce; Sailaja Paruchuri
Journal:  J Allergy Clin Immunol       Date:  2015-08-05       Impact factor: 10.793

6.  RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis.

Authors:  Gordon S Wong; Jamie L Redes; Nariman Balenga; Morgan McCullough; Nathalie Fuentes; Ameya Gokhale; Cynthia Koziol-White; Joseph A Jude; Laura A Madigan; Eunice C Chan; William H Jester; Sabrina Biardel; Nicolas Flamand; Reynold A Panettieri; Kirk M Druey
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

7.  Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.

Authors:  Katherine N Cahill; Benjamin A Raby; Xiaobo Zhou; Feng Guo; Derek Thibault; Andreas Baccarelli; Hyang-Min Byun; Neil Bhattacharyya; John W Steinke; Joshua A Boyce; Tanya M Laidlaw
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

Review 8.  NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.

Authors:  Tanya M Laidlaw; Joshua M Levy
Journal:  Curr Allergy Asthma Rep       Date:  2020-03-14       Impact factor: 4.806

9.  Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Julie Negri; Lixia Liu; Spencer C Payne; Larry Borish
Journal:  J Immunol       Date:  2014-06-02       Impact factor: 5.422

Review 10.  Prostaglandins in asthma and allergic diseases.

Authors:  R Stokes Peebles
Journal:  Pharmacol Ther       Date:  2018-08-03       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.